https://www.selleckchem.com/products/tcpobop.html
high predictivity, despite missing data. ( www.clinicaltrials.gov , NCT01117441, first submitted date May 3, 201. Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to evaluate the pharmacokinetic properties of once-daily amikacin liposome inhalation suspension (ALIS) in patients with treatment-refractory NTM lung disease. In phase 2 (TR02-112) and phase 3 (CONVERT)
Like
Comment
Share
